Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

A comparative study of CSF neurofilament light and heavy chain protein in MS.

Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, Nissim A, Malaspina A, Leppert D, Giovannoni G, Kappos L.

Mult Scler. 2013 Oct;19(12):1597-603. doi: 10.1177/1352458513482374. Epub 2013 Mar 25.

PMID:
23529999
2.

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.

Kuhle J, Malmeström C, Axelsson M, Plattner K, Yaldizli O, Derfuss T, Giovannoni G, Kappos L, Lycke J.

Acta Neurol Scand. 2013 Dec;128(6):e33-6. doi: 10.1111/ane.12151. Epub 2013 Jun 13.

PMID:
23763388
3.

The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA.

Koel-Simmelink MJ, Vennegoor A, Killestein J, Blankenstein MA, Norgren N, Korth C, Teunissen CE.

J Immunol Methods. 2014 Jan 15;402(1-2):43-9. doi: 10.1016/j.jim.2013.11.008. Epub 2013 Nov 22.

PMID:
24275679
4.

A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.

Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lindberg RL, Petzold A.

J Neuroimmunol. 2010 Mar 30;220(1-2):114-9. doi: 10.1016/j.jneuroim.2010.01.004. Epub 2010 Feb 1.

PMID:
20117845
5.

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J.

J Neurol. 2011 May;258(5):882-8. doi: 10.1007/s00415-010-5863-2. Epub 2011 Jan 1.

PMID:
21197541
6.

Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RH, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G.

J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):206-11.

7.

Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica.

Wang H, Wang C, Qiu W, Lu Z, Hu X, Wang K.

Neurochem Int. 2013 Dec;63(8):805-8. doi: 10.1016/j.neuint.2013.10.008. Epub 2013 Oct 23.

PMID:
24161620
8.

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.

Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, Schepens M, Bouwman F, Twaalfhoven HA, Blom HJ, Jakobs C, Dijkstra CD.

Neurology. 2009 Apr 14;72(15):1322-9. doi: 10.1212/WNL.0b013e3181a0fe3f.

PMID:
19365053
9.

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å, Liman V, Norgren N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61. doi: 10.1515/cclm-2015-1195.

PMID:
27071153
10.

Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.

Fialová L, Bartos A, Svarcová J, Zimova D, Kotoucova J, Malbohan I.

J Neuroimmunol. 2013 Sep 15;262(1-2):113-20. doi: 10.1016/j.jneuroim.2013.06.010. Epub 2013 Jul 17.

PMID:
23870535
11.

Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury.

Rejdak K, Kuhle J, Rüegg S, Lindberg RL, Petzold A, Sulejczak D, Papuc E, Rejdak R, Stelmasiak Z, Grieb P.

Epilepsia. 2012 May;53(5):922-7. doi: 10.1111/j.1528-1167.2012.03459.x. Epub 2012 Apr 17.

12.

Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy.

Petzold A, Thompson EJ, Keir G, Quinn N, Holmberg B, Dizdar N, Wenning GK, Rascol O, Tolosa E, Rosengren L.

J Neurol Sci. 2009 Apr 15;279(1-2):76-9. doi: 10.1016/j.jns.2008.12.037. Epub 2009 Feb 4.

PMID:
19195665
13.

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.

Malmeström C, Haghighi S, Rosengren L, Andersen O, Lycke J.

Neurology. 2003 Dec 23;61(12):1720-5.

PMID:
14694036
14.

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.

Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony DC, Kappos L, Lindberg RL.

Neurology. 2011 Apr 5;76(14):1206-13. doi: 10.1212/WNL.0b013e31821432ff. Epub 2011 Feb 23.

PMID:
21346223
15.

Neurofilaments as biomarkers in multiple sclerosis.

Teunissen CE, Khalil M.

Mult Scler. 2012 May;18(5):552-6. doi: 10.1177/1352458512443092. Epub 2012 Apr 4. Review.

PMID:
22492131
16.

Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis.

Steinacker P, Fang L, Kuhle J, Petzold A, Tumani H, Ludolph AC, Otto M, Brettschneider J.

PLoS One. 2011;6(8):e23600. doi: 10.1371/journal.pone.0023600. Epub 2011 Aug 15.

17.

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome.

Khalil M, Enzinger C, Langkammer C, Ropele S, Mader A, Trentini A, Vane ML, Wallner-Blazek M, Bachmaier G, Archelos JJ, Koel-Simmelink MJ, Blankenstein MA, Fuchs S, Fazekas F, Teunissen CE.

Mult Scler. 2013 Apr;19(4):436-42. doi: 10.1177/1352458512458010. Epub 2012 Aug 23.

18.

Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.

Brettschneider J, Petzold A, Süssmuth SD, Landwehrmeyer GB, Ludolph AC, Kassubek J, Tumani H.

Mov Disord. 2006 Dec;21(12):2224-7.

PMID:
17013909
19.

Neurofilament and glial fibrillary acidic protein in multiple sclerosis.

Norgren N, Sundström P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M.

Neurology. 2004 Nov 9;63(9):1586-90.

PMID:
15534240
20.

Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.

Håkansson I, Tisell A, Cassel P, Blennow K, Zetterberg H, Lundberg P, Dahle C, Vrethem M, Ernerudh J.

Eur J Neurol. 2017 May;24(5):703-712. doi: 10.1111/ene.13274. Epub 2017 Mar 6.

PMID:
28261960

Supplemental Content

Support Center